Isodiol International Inc. – Delay In Filing Audited Financial Statements – Obtains Management Cease Trade Order from BCSC
July 30, 2019 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF)
(FSE: LB6B.F)(the “Company” or “Isodiol”), today announces a delay in the filing of its audited
annual financial statements, related management’s discussion and analysis and supporting
officer certificates for the financial year ended March 31, 2019 (the “Filings”). The Filings are
required to be made with the relevant securities regulatory authorities on or before July 29,
2019.
The anticipated delay of its Filings is a result of delays in getting access to accounting
information pursuant to dispositions of subsidiaries for which the Company no longer has
management influence over.
The Company notes that such delays have been resolved and the Company is now in the final
stages of the audit and anticipates completing its Filings before August 16, 2019.
The Company has obtained a management cease trade order from the relevant securities
regulators as contemplated by National Policy 12-203 Management Cease Trade Orders of the
Canadian Securities Administrators. The Company will comply with the requirements of the
alternative information guidelines set out in the National Policy. The Company is not subject to
any insolvency proceedings.
The Company also announces the departure of Kevin Swadish, Chief Revenue Officer and
Patrick Ogle as a Director and Chief Operating Officer of the Company.
Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/,
on Twitter @Isodiolintlinc, and on Instagram @isodiol.
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-thecounter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
[email protected]
604-409-4409
MEDIA CONTACT:
Christopher Hussey
[email protected]
The CSE has not reviewed, approved or disapproved the content of this press release.
Forward-Looking Information: This news release contains “forward-looking information” within
the meaning of applicable securities laws relating to statements regarding the Company’s
business, proposed arrangement with creditors, products and future the Company’s business, its
product offerings and plans for sales and marketing. Although the Company believes that the
expectations reflected in the forward-looking information are reasonable, there can be no
assurance that such expectations will prove to be correct. Readers are cautioned not to place
undue reliance on forward-looking information. Such forward-looking statements are subject to
risks and uncertainties that may cause actual results, performance and developments to differ
materially from those contemplated by these statements depending on, among other things, the
risks that the Company’s products and plan will vary from those stated in this news release and
the Company may not be able to carry out its business plans as expected. Except as required by
law, the Company expressly disclaims any obligation and does not intend, to update any forwardlooking
statements or forward-looking information in this news release. Although the Company
believes that the expectations reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be correct and makes no reference to
profitability based on sales reported. The statements in this news release are made as of the date
of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.